SEC Filings

Form F-1
AURIS MEDICAL HOLDING AG filed this Form F-1 on 02/09/2018
Document Outline
Entire Document (517 KB)
Subdocument 1 - F-1 - FORM F-1
Page 1 - Filed with the Securities and Exchange Commission on February 9, 2018
Page 2 - PRELIMINARY PROSPECTUS
Page 3 - Page
Page 4 - This summary highlights information contained elsewhere in this prospectus. This summary may not con
Page 5 - Nasdaq Listing Requirements
Page 6 - N/A
Page 7 - This summary highlights information presented in greater detail elsewhere in this prospectus. This s
Page 8 - N/A
Page 9 - Any investment in our common shares involves a high degree of risk. You should carefully consider th
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - Gewinnvortrag
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - Aktienkapital
Page 29 - The Board of Directors is authorized at any time until 13 April 2019 to increase the share capital b
Page 30 - Erm chtigungsbeschluss
Page 31 - not more than 6,500,000 registered shares, which shall be fully paid-in, with a nominal value of CHF
Page 32 - N/A
Page 33 - Gewinnvortrag
Page 34 - Wertrechte
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - Schweizerisches Obligationenrecht)
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - The following summary contains a description of the material Swiss and U.S. federal income tax conse
Page 46 - Nennwertr ckzahlungen
Page 47 - Teilbesteuerung
Page 48 - Emissionsabgabe
Page 49 - de minimis
Page 50 - Taxation of Distributions
Page 51 - N/A
Page 52 - Securities Act
Page 53 - N/A
Page 54 - N/A
Page 55 - N/A
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - N/A
Page 60 - N/A
Page 61 - N/A
Page 62 - N/A
Page 63 - N/A
Subdocument 2 - EX-5.1 - EXHIBIT 5.1
Page 1 - Exhibit 5.1
Page 2 - Documents
Page 3 - Documents
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Subdocument 3 - EX-23.1 - EXHIBIT 23.1
Page 1 - Exhibit 23.1